For those of you wishing to dabble in the more complex aspects of AAS I would recommend reading the following.

http://jpet.aspetjournals.org/content/281/1/93.full

For those of you who do not have the time, the desire, or the ability to digest the research I summarize below.

This particular study deals with Nandrolone Esters, where it is injected, and how it is dosed milligram per milliliter and the effects that these variables have on peak plasma levels as well as half-lives. Here are a few points to consider.

• Higher dosed milligram per milliliter leads to a more rapid peak plasma levels and shorter half-lives for the same ester.
• Peak plasma levels and half-lives are determined by the ester but can be manipulated via site injection and milligram per milliliter concentrations.
• “Thus, the bioavailability and physiological effects of a nandrolone ester in an oil vehicle are greatest when the ester is injected in a small (1 ml vs. 4 ml) volume and into the gluteal vs. deltoid muscle.”

Although this study was done with Nandrolone Esters I believe it has merit and can be extrapolated to all the other compounds that we utilize (that utilize oil as a carrier base). I summed up this in the simplest matter possible so that everybody can gain the knowledge. I highly recommend one invest the time to read the whole study.

Hopefully this helps the community.

Remember this content is provided strictly for information and entertainment purposes.